Přejít k obsahu
Merck
Všechny fotografie(1)

Hlavní dokumenty

Zobrazit celou dokumentaci

SML2487

Sigma-Aldrich

Cabazitaxel

≥95% (HPLC)

Synonyma:

1-hydroxy-7β,10β-dimethoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-[[(tert-butoxy)carbonyl]amino]-2-hydroxy-3-phenylpropanoate], DEP cabazitaxel, Jevtana, TXD 258, XRP 6258, XRP-6258, dimethoxydocetaxel

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C45H57NO14
Číslo CAS:
183133-96-2
Molekulová hmotnost:
835.93
MDL number:
MFCD18827611
UNSPSC Code:
12352200
NACRES:
NA.77

assay

≥95% (HPLC)

form

powder

optical activity

[α]/D -36 to -44°, c = 0.5 in methanol

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

InChI

1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1

InChI key

BMQGVNUXMIRLCK-OAGWZNDDSA-N

Biochem/physiol Actions

Cabazitaxel is a synthetic taxane microtubule inhibitor and anticancer agent. It acts by stabilization of microtubules, promoting tubulin assembly into microtubules but inhibiting disassembly, resulting in the inhibition of mitotic and interphase cellular functions.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Muta. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 2

1 of 2

Vincristine sulfate salt 95.0-105.0% (HPLC), powder or crystals

Sigma-Aldrich

V8879

Vincristine sulfate salt

Paclitaxel from Taxus brevifolia, ≥95% (HPLC), powder

Sigma-Aldrich

T7402

Paclitaxel

Sheel A Patel et al.
OncoTargets and therapy, 10, 4089-4098 (2017-09-02)
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are now multiple effective and approved agents for
Patricia Vrignaud et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 19(11), 2973-2983 (2013-04-17)
Taxanes are important chemotherapeutic agents with proven efficacy in human cancers, but their use is limited by resistance development. We report here the preclinical characteristics of cabazitaxel (XRP6258), a semisynthetic taxane developed to overcome taxane resistance. Cabazitaxel effects on purified
Maria J Martinez et al.
iScience, 26(9), 107681-107681 (2023-09-14)
Men with incurable castration resistant prostate cancer (CRPC) are typically treated with taxanes; however, drug resistance rapidly develops. We previously identified a clinically relevant seven gene network in aggressive CRPC, which includes the spindle assembly checkpoint (SAC) kinase BUB1. Since
Takeo Kosaka et al.
Cancer chemotherapy and pharmacology, 82(6), 1061-1066 (2018-10-05)
The correlation of the oncological outcomes of docetaxel and cabazitaxel in Japanese metastatic castration-resistant prostate cancer (mCRPC) patients has not been unclear. This study included a total of 47 consecutive Japanese mCRPC patients treated with cabazitaxel and assessed the prognostic
Buse Cevatemre et al.
Cell death & disease, 15(2), 132-132 (2024-02-13)
The development of taxane resistance remains a major challenge for castration resistant prostate cancer (CR-PCa), despite the effectiveness of taxanes in prolonging patient survival. To uncover novel targets, we performed an epigenetic drug screen on taxane (docetaxel and cabazitaxel) resistant

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.